<DOC>
	<DOCNO>NCT00057798</DOCNO>
	<brief_summary>RATIONALE : Determination genetic change patient non-small cell lung cancer may help predict outcome treatment . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug , give surgery , may shrink tumor remove surgery . PURPOSE : Phase II trial study genetic change effectiveness combine vinorelbine gemcitabine surgery treat patient stage IB , stage II , stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Genetic Changes Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine Gemcitabine Before Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine frequency expression epithelial marker CK19 , CK20 , MUC1 , MUC5 ( reverse transcriptase-polymerase chain reaction ) lymph node tissue blood sample patient resectable stage IB-III non-small cell lung cancer treat neoadjuvant vinorelbine gemcitabine follow surgery . - Determine expression multidrug resistance-associated protein gene treatment regimen patient . - Determine global expression profile gene ( microarray technology ) tumor tissue patient treat regimen . - Determine frequency loss heterozygosity several loci chromosome 3p , 9p , 11p treatment regimen patient . - Determine percent positivity cell stain MCM2 CDC6 ( prereplicative complex ) immunohistochemistry treatment regimen patient . - Determine feasibility regimen patient . - Determine pathological response rate patient treated regimen . - Determine side effect regimen patient . - Determine disease-free overall survival patient treat regimen . - Determine autologous immune response patient treat regimen . OUTLINE : Patients receive vinorelbine IV 6-10 minute gemcitabine IV 30 minute day 1 , 8 , 22 , 29 absence disease progression unacceptable toxicity . Patients disease progression scan bronchoscopy undergo surgical resection day 57-70 ( week 8-10 ) . Loss heterozygosity ( LOH ) loci chromosome 3p , 9p , 11p assess blood specimen , tumor tissue , noncancerous tissue chemotherapy . Specimens also examine molecular marker occult metastasis use reverse transcriptase-polymerase chain reaction . Multidrug resistance-associated protein gene expression also determine use microarray technology . Patients follow every 3 month 2 year , every 6 month 5 year , annually thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell carcinoma lung May confirm initial bronchoscopy mediastinoscopy Stage IB ( T2 , N0 , M0 ) Stage IIA ( T1 , N1 , M0 ) Stage IIB ( T23 , N01 , M0 ) Stage IIIA ( T13 , N12 , M0 ) stage IIIB ( 2 lesion 1 lobe [ T4 ] ) No N3 lymph node ( contralateral mediastinal/hilar supraclavicular/scaline ) OR T4 primary tumor ( malignant pleural effusion mediastinal invasion ) clinical stag criterion ( see CT PET scan proven mediastinoscopy ) No metastatic disease ( except N1 N2 disease ) malignant pleural effusion* detect preoperative evaluation No exudative effusion ( even cytologically negative ) Pleural fluid consider exudative follow apply : Ratio pleural fluid protein serum protein great 0.5 Ratio pleural fluid lactic dehydrogenase ( LDH ) serum LDH least 0.6 Pleural fluid LDH great 200 IU/L No multiple area fluorodeoxyglucose ( FDG ) uptake** outside area primary tumor lung NOTE : *Effusions visible CT scan large enough safe thoracentesis allow NOTE : **If 1 area show increase FDG uptake , area concern require evaluation ( e.g. , biopsy ) exclude metastatic disease Bidimensionally measurable evaluable disease* NOTE : *Lesions apparent chest CT scan ( e.g. , illdefined mass associate post obstructive change mediastinal hilar adenopathy measurable 1 dimension ) consider evaluable PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic Bilirubin great 1.5 mg/dL AST ALT great 1.5 time upper limit normal Renal Creatinine great 1.5 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Deemed medically fit surgical resection No active malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ cervix No psychological , sociological , geographical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Concurrent participation RPCI vaccine study ( postoperative vaccination autologous tumorassociated antigenpulsed dendritic cell ) allow Chemotherapy No prior chemotherapy lung cancer No concurrent participation another study involve chemotherapy agent Endocrine therapy Not specify Radiotherapy No prior radiotherapy lung cancer No concurrent participation another study involve radiotherapy Surgery No prior surgery lung cancer More 3 month since prior major surgery ( e.g. , coronary artery bypass graft ) Other No prior therapy lung cancer No concurrent antineoplastic agent Concurrent participation observational study require bloodwork , radiograph , pulmonary function test , quality life study allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>